Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: plhky3465 who wrote (50173)	2/8/2019 2:23:17 PM
From: ladyPI	9 Recommendations Recommended By btlbail1 corndog fatboy14 idahoranch1 jhcimmu and 4 more members Read Replies (1) \| Respond to of 63283

$25 is a no from me

To: plhky3465 who wrote (50173)	2/8/2019 2:26:03 PM
From: zevenhuizen	9 Recommendations Recommended By allatwwk bnutman bobbseytwins2001 Dietman erippetoe and 4 more members Respond to of 63283

Been here , like many others, since the nineties. Not a buy and hold, there have been times I have been out completely, but mostly holding a core and trade around. The most important fact is that the drug works, all other issues are solvable so I, fortunately, from an investment point of view can afford to let this play out. Still looks like a very nice rate of return on an investment to me if you would buy today. I really feel bad for patients that need this drug though , from that perspective it should have been approved yesterday.

To: plhky3465 who wrote (50173)	2/8/2019 4:31:14 PM
From: allatwwk	Read Replies (1) \| Respond to of 63283

Phil, for the record, I'd be disappointed with a $25-ish buyout price. Get close to $50 and my vote becomes a yes. 132 in the right hands is worth it, probably more. The drug itself didn't miss, but the mfg did -- other companies have the expertise to get this right. Alas, I think the problem is temporary. IMMU will outsource all its mfg by 2021, with a lab scale operation for research/testing needs. On a slightly different track, I've thought of this mgmt team by using a metaphor from hockey. You go where the puck is headed rather than where it is. To me, this mgmt team is well-suited to run a mid-tier biopharma, which is where IMMU is headed. I never had a sense that getting from a productive science lab to functional internal manufacturing was a management strength. I did think they'd be good enough to get this done for AA, but apparently not.